Palisade Bio Inc. (PALI): Price and Financial Metrics
PALI Price/Volume Stats
| Current price | $3.56 | 52-week high | $22.35 |
| Prev. close | $3.58 | 52-week low | $3.30 |
| Day low | $3.51 | Volume | 3,020 |
| Day high | $3.58 | Avg. volume | 492,358 |
| 50-day MA | $3.90 | Dividend yield | N/A |
| 200-day MA | $6.00 | Market Cap | 3.33M |
PALI Stock Price Chart Interactive Chart >
Palisade Bio Inc. (PALI) Company Bio
Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier. The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In clinical studies, LB1148 has demonstrated positive results in reducing the incidence and severity of post-surgical abdominal adhesions and accelerating the time to return of postoperative bowel function. LB1148 is being investigated in a Phase 2 study to evaluate return of gastrointestinal function, post-operative ileus and intra-abdominal adhesions in subjects undergoing elective bowel resection. (copied from company website @ https://www.palisadebio.com/about-us/)
Latest PALI News From Around the Web
Below are the latest news stories about PALISADE BIO INC that investors may wish to consider to help them evaluate PALI as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday! |
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment of moderate-to-severe ulcerative colitis (UC) is anticipated to commence Phase 1 clinical study in 2024 – Strong financial position with cash to execute on strategy and achieve significant milestones into 2025 Carlsbad, CA, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade |
Palisade Bio to Participate at the Virtual Investor Ask the CEO ConferenceLive moderated webcast with J.D. Finley, Chief Executive Officer of Palisade Bio on Wednesday, October 25th at 2:00 PM ET Carlsbad, CA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio (Nasdaq: PALI), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that J.D. Finley, Chief Executive Officer of Palisade Bio will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 2:00 PM |
Insider Buying: John Finley Acquires 15,000 Shares of Palisade Bio IncOn September 13, 2023, John Finley, CEO, CFO, and Director of Palisade Bio Inc (NASDAQ:PALI), made a significant insider purchase of 15,000 shares of the company's stock. |
Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq RulesCarlsbad, CA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for the registered direct offe |
PALI Price Returns
| 1-mo | -0.56% |
| 3-mo | -20.18% |
| 6-mo | -35.42% |
| 1-year | -67.49% |
| 3-year | -99.84% |
| 5-year | -100.00% |
| YTD | -59.77% |
| 2023 | -88.65% |
| 2022 | -92.00% |
| 2021 | -75.38% |
| 2020 | -99.70% |
| 2019 | -99.20% |
Loading social stream, please wait...